Cargando…

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies. 5-AZA-CdR can reactivate tumor suppressor genes si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karahoca, Metin, Momparler, Richard L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570332/ https://www.ncbi.nlm.nih.gov/pubmed/23369223 http://dx.doi.org/10.1186/1868-7083-5-3

Ejemplares similares

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
por: Lemaire, Maryse, et al.
Publicado: (2008)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
por: Momparler, Richard L., et al.
Publicado: (2021)

Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
por: Hurtubise, Annie, et al.
Publicado: (2008)

The Effect of 5-aza,2’-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines
por: Sanaei, Masumeh, et al.
Publicado: (2023)

5-Aza-2′-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts
por: Alpoim-Moreira, Joana, et al.
Publicado: (2023)

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
por: Jansen, Yanina J L, et al.
Publicado: (2019)

5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
por: Patra, Aditi, et al.
Publicado: (2011)

Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
por: Tomita, Tatsunosuke, et al.
Publicado: (2017)

Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
por: Chiang, Tung-chin, et al.
Publicado: (2019)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
por: Maslov, Alexander Y., et al.
Publicado: (2012)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
por: Tsai, Chiou-Tsun, et al.
Publicado: (2013)

Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the Transcriptome
por: Qiu, Xiangning, et al.
Publicado: (2010)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1
por: Bouchat, Sophie, et al.
Publicado: (2015)

DNA demethylation caused by 5-Aza-2′-deoxycytidine induces mitotic alterations and aneuploidy
por: Costa, Giuseppe, et al.
Publicado: (2016)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Effects of 5-aza-2´-deoxycytidine on primary human chondrocytes from osteoarthritic patients
por: Kadler, Shirin, et al.
Publicado: (2020)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

HSPB6 Is Depleted in Colon Cancer Patients and Its Expression Is Induced by 5-aza-2′-Deoxycytidine In Vitro
por: Almutairi, Bader O., et al.
Publicado: (2023)

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
por: Cortvrindt, R., et al.
Publicado: (1987)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
por: Ding, Xiao-Lei, et al.
Publicado: (2016)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Gene expression profiling of the synergy of 5-aza-2(′)-deoxycytidine and paclitaxel against renal cell carcinoma
por: Han, Tiandong, et al.
Publicado: (2012)

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma
por: Hassler, Melanie R., et al.
Publicado: (2012)

DNA demethylation by 5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences
por: Ramos, María-Paz, et al.
Publicado: (2015)

The Cockayne syndrome protein B is involved in the repair of 5-AZA-2′-deoxycytidine-induced DNA lesions
por: Burgos-Morón, Estefanía, et al.
Publicado: (2018)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma
por: Geiger, Kathrin, et al.
Publicado: (2012)

Global Demethylation of Rat Chondrosarcoma Cells after Treatment with 5-Aza-2′-Deoxycytidine Results in Increased Tumorigenicity
por: Hamm, Christopher A., et al.
Publicado: (2009)

Regulation of TIMP-1 in Human Placenta and Fetal Membranes by lipopolysaccharide and demethylating agent 5-aza-2'-deoxycytidine
por: Vincent, Zoë L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6orvhec3n2gcakt2p54q0fqsf7